Statements (151)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:drones |
| gptkbp:accessories |
carrying case
extra batteries propeller guards spare parts kit |
| gptkbp:administration_timing |
preoperatively
|
| gptkbp:administration_volume |
up to 20 m L
|
| gptkbp:aircraft_operated |
2 hours
|
| gptkbp:application |
gptkb:military
gptkb:search_and_rescue agriculture disaster management environmental monitoring |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
prescription only
|
| gptkbp:battery_type |
gptkb:Li_Po
|
| gptkbp:class |
anesthetics
|
| gptkbp:clinical_trial |
gptkb:United_States
Phase 2 Phase 3 positive efficacy acceptable safety profile ARX Therapeutics Arixa Pharmaceuticals |
| gptkbp:clinical_use |
pain management
|
| gptkbp:collaborations |
academic institutions
clinical research organizations |
| gptkbp:color_options |
gptkb:black
gptkb:white gptkb:camouflage |
| gptkbp:communication_system |
gptkb:radio_station
|
| gptkbp:contraindication |
respiratory depression
severe liver disease severe hepatic impairment allergy to buprenorphine hypersensitivity to bupivacaine |
| gptkbp:control_system |
gptkb:remote_control
|
| gptkbp:developed_by |
ARX Therapeutics
Arixa Pharmaceuticals |
| gptkbp:development |
ongoing
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:drug_interactions |
anticoagulants
CYP450 inducers CYP450 inhibitors other anesthetics CYP3 A4 inducers CYP3 A4 inhibitors |
| gptkbp:duration |
short-term
|
| gptkbp:elevation |
3000 meters
|
| gptkbp:features |
GPS navigation
HD camera real-time video transmission autonomous flight mode |
| gptkbp:first_flight |
gptkb:2021
|
| gptkbp:formulation |
oral
liposomal liposomal bupivacaine |
| gptkbp:future_prospects |
chronic pain management
combination therapies cost-effectiveness studies healthcare provider education real-world evidence studies long-term efficacy different formulations pediatric applications post-surgical pain management patient adherence strategies |
| gptkbp:has_programs |
ARX Control Suite
|
| https://www.w3.org/2000/01/rdf-schema#label |
ARX-01
|
| gptkbp:indication |
surgical site infiltration
|
| gptkbp:ingredients |
gptkb:buprenorphine
gptkb:bupivacaine |
| gptkbp:invention |
patented
ARX Therapeutics |
| gptkbp:landing_distance |
gptkb:parachute
|
| gptkbp:launch_date |
gptkb:2011
|
| gptkbp:launch_window |
gptkb:catapult
|
| gptkbp:manufacturer |
ARX Robotics
|
| gptkbp:market_position |
investigational
|
| gptkbp:marketed_as |
Exparel
|
| gptkbp:max_speed |
120 km/h
|
| gptkbp:mechanism_of_action |
gptkb:surgery
opioid receptor agonist |
| gptkbp:packaging |
vial
|
| gptkbp:pain_relief_duration |
up to 72 hours
|
| gptkbp:patient_education |
monitor for side effects
follow-up appointments recommended avoid driving after administration report severe pain |
| gptkbp:patient_population |
adults
|
| gptkbp:payload_capacity |
5 kg
|
| gptkbp:pharmacokinetics |
extended release
|
| gptkbp:phase1_study_results |
well tolerated
|
| gptkbp:phase2_study_results |
improved quality of life
reduced opioid consumption significant pain reduction |
| gptkbp:price |
high
$15,000 |
| gptkbp:provides_guidance_on |
gptkb:American_Pain_Society
gptkb:American_Society_of_Anesthesiologists |
| gptkbp:purpose |
surveillance
|
| gptkbp:range |
150 km
|
| gptkbp:regulatory_compliance |
FAA regulations
FDA approval not approved |
| gptkbp:released |
gptkb:2022
|
| gptkbp:research |
randomized controlled trials
|
| gptkbp:research_focus |
pain management
postoperative analgesia |
| gptkbp:route_of_administration |
oral
injection |
| gptkbp:sensor |
gptkb:missile
infrared sensor LIDAR |
| gptkbp:service_frequency |
as needed
single dose |
| gptkbp:side_effect |
dizziness
headache nausea vomiting seizures constipation sedation infection risk hypotension nerve injury cardiac toxicity local site reactions |
| gptkbp:storage |
room temperature
|
| gptkbp:support |
1 year warranty
|
| gptkbp:target_audience |
surgical patients
postoperative patients |
| gptkbp:targets |
pain
|
| gptkbp:training |
yes
|
| gptkbp:treatment |
improved pain control
reduced opioid consumption |
| gptkbp:type |
gptkb:unmanned_aerial_vehicle
|
| gptkbp:upgrades |
yes
|
| gptkbp:used_for |
postoperative recovery
postoperative pain |
| gptkbp:user_interface |
gptkb:mobile_app
|
| gptkbp:user_reviews |
positive
high performance reliable easy to use good customer support |
| gptkbp:weight |
10 kg
|
| gptkbp:wingspan |
3 meters
|
| gptkbp:bfsParent |
gptkb:Acel_Rx_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|